Empowering Primary Care Through Evidence

PEER is a primary care led evidence based medicine team focused on providing relevant evidence to family physicians and primary care providers.

PEIP Conference 2021

PEER hosts an annual conference that provides practical primary care focused education based on the highest quality evidence and is free of industry bias.

We are currently preparing our for this year's conference, stay tuned for details.

More Information

Pain
Calculator

Osteoarthritis
Decision Aid

Most Recent Tools for Practice

Tools for Practice #297 – Opening a can of helminths: Ivermectin for COVID-19

Does ivermectin improve clinical outcomes in COVID-19?

BOTTOM LINE: The best available evidence does not show that ivermectin improves clinically important outcomes in COVID-19. Use in COVID-19 is discouraged. Read More

7 September 2021

Tools for Practice #296 – Frequent migraines are a headache: Can biologics help?

What is the efficacy of Calcitonin Gene Related Peptide (CGRP) inhibitors in migraine prophylaxis?

BOTTOM LINE: For patients with episodic and chronic migraines, treating 5-8 patients with a CGRP-inhibitor will lead to one patient experiencing at least a 50% reduction in monthly migraine days compared to placebo. From baseline, a decrease of 1-2 monthly migraine days may be seen. Cost may limit use. Read More

23 August 2021

Tools for Practice #295 – Mission Slimpossible: Semaglutide for weight loss

Is semaglutide effective for weight loss?

BOTTOM LINE: Used with lifestyle changes, 2.4mg weekly subcutaneous semaglutide resulted in an average 10-15% loss in weight (10- 15kg) over 68 weeks versus 2-3% (3-4kg) with placebo. Most (70- 80%) semaglutide participants lost 5% or more of their body weight. About ¾ of patients experienced gastrointestinal side effects, but few stop. Weight regain occurs once the medication is stopped. Read More

27 July 2021

Tools for Practice #294 – Real World Evidence for COVID-19 Vaccines

What is the real-world effectiveness for currently available COVID-19 vaccines?

BOTTOM LINE: Similar to clinical trials, real world cohort and case-control studies find COVID-19 infections are reduced by >90% with two doses of mRNA vaccines. Single doses of either mRNA or AstraZeneca vaccine decreases infections by ~60% and hospitalizations by 70-80%. Vaccine effectiveness appears similar for variants of concern and are safe for pregnant women. Read More

12 July 2021

Tools for Practice #293 – Bath Time: Atopic Dermatitis and Bathing

Can atopic dermatitis (AD) be improved with more baths/showers, bleach baths, or bath additives?

BOTTOM LINE: In AD, more frequent baths (and likely showers), 1-2 times/day, improve symptoms meaningfully (≥30%) for about 40% more patients than less frequent bathing (with moisturizers after bath/showers). Despite advocacy, research does not support bleach baths, bath additives or water softeners for AD symptoms. Offer simple advice for frequent plain-water bathing and application of moisturizers immediately afterward. Read More

28 June 2021

PEER Values

When creating primary care education and programs, the PEER team focuses on minimizing bias, patient orientated outcomes, shared decision making, collaboration and most importantly simplicity.

Who is PEER?

Patients, Experience, Evidence and Research (PEER) was formed between a group of primary care providers who shared a common belief that evidence should be made accessible to all primary care providers.

Follow @peerevidence on Instagram

Our Partners